| Literature DB >> 29899691 |
Franca Tecchio1, Carlo Cottone1, Camillo Porcaro1,2,3, Andrea Cancelli1, Vincenzo Di Lazzaro4, Giovanni Assenza4.
Abstract
Focal epilepsy is a network pathology, where the brain connectivity of the epileptic focus (EF) influences seizure frequency and cortical dysfunction. Growing evidence supports a clinical efficacy of cathodal transcranial direct current stimulation (ctDCS) in drug-resistant epilepsy (DRE). ctDCS effects can be merely attributed to the inhibition of cortical excitability, which is abnormally increased in epilepsy, but its effect on brain network of DRE patients has never been reported. We aimed at exploring the hypothesis that functional connectivity (FC) changes may explain part of ctDCS clinical effects in DRE patients. We assessed the ctDCS-induced changes of electroencephalography-derived brain FC of a group of six temporal lobe DRE patients receiving a seizure reduction after ctDCS. By a single-subject eLORETA analysis, we compared the FC among the EF region and other nine bilateral macro-regions, before and after Real and Sham ctDCS in a double-blind Sham-controlled crossover design. FC changed after Real ctDCS in all patients despite no appreciable changes occurred after Sham. Most of FC changes (73%) involved the EF region. The epileptic seizure reduction correlated with the increase of the EF FC, in the whole frequency band and in the theta band. This small-sample analysis clearly revealed that ctDCS induced FC changes in the brain network of temporal lobe DRE patients. Our data support the hypothesis that FC changes may contribute to explain the effects of ctDCS in epilepsy, offering a new scenario in the personalization of neuromodulation interventions in epileptic people.Entities:
Keywords: drug-resistant; electroencephalography; epilepsy; functional connectivity; transcranial direct current stimulation (tDCS)
Mesh:
Year: 2018 PMID: 29899691 PMCID: PMC5988884 DOI: 10.3389/fncir.2018.00044
Source DB: PubMed Journal: Front Neural Circuits ISSN: 1662-5110 Impact factor: 3.492
Demographical and clinical data of participants.
| ID | Gender | Age (years) | Diagnosis | Seizures type | EF | Years from 1st seizure | AEDs (mg/die) |
|---|---|---|---|---|---|---|---|
| S.C. | 24 | Cryptogenic | CP | T4 | 20 | FLB 2400 LTG 400 | |
| A.C. | 50 | Cryptogenic | CP+SG | F8 | 45 | CBZ 1400 VPA1800 | |
| C.T. | 17 | Symptomatic (diabetes type I, brainstem atrophy, retinitis pigmentosa) | CP+SG | F7 | 10 | PB 100 CBZ 1200 CLB 20 | |
| S.B. | 23 | Symptomatic (meningitis) | CP+SG | T4 | 22 | PB 100 LEV 3500 | |
| L.P. | 53 | Symptomatic (delivery problems) | CP+SG | T4 | 49 | LTG 150 | |
| I.C. | 36 | Cryptogenic | CP | T5 | 31 | CBZ 400 TPM 100 | |
Clinical and functional connectivity changes after ctDCS.
| PT | Seizures | Functional connectivity changes | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Pre-ctDCS | Post-ctDCS | Pre–post | TOTAL | Epileptic focus | Epileptic focus (%) | Epileptic focus (theta) | Epileptic focus (alpha) | Epileptic focus (beta) | |
| DRE1 | 1 | 1 | 0 | 3 | 3 | 100 | 0 | 2 | 1 |
| DRE2 | 1 | 0 | 1 | -51 | -28 | 55 | -1 | -19 | -8 |
| DRE3 | 1 | 0 | 1 | 4 | 3 | 75 | 0 | 3 | 0 |
| DRE4 | 10 | 0 | 10 | 29 | 12 | 41 | 3 | 0 | 9 |
| DRE5 | 100 | 3 | 97 | 15 | 16 | 100 | 8 | 7 | 1 |
| DRE6 | 27 | 13 | 14 | 128 | 88 | 69 | 12 | 25 | 51 |
| Median | 5.5 | 0.5 | 5.5 | 9.5 | 14.0 | 73 | 1.5 | 2.5 | 1 |
| Range | [1, 100] | [0, 13] | [0, 97] | [-51, 128] | [3, 88] | 24 | [-1, 12] | [-19, 25] | [-8, 51] |